Lalitha Shankar
Overview
Explore the profile of Lalitha Shankar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
2067
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakajima E, Simpson A, Bogaerts J, de Vries E, Do R, Garalda E, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300687.
PMID: 38635935
Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working...
2.
Bou-Samra P, Muhammad N, Chang A, Karsalia R, Azari F, Kennedy G, et al.
J Biomed Opt
. 2023 May;
28(5):050901.
PMID: 37193364
Significance: This third biennial intraoperative molecular imaging (IMI) conference shows how optical contrast agents have been applied to develop clinically significant endpoints that improve precision cancer surgery. Aim: National and...
3.
Trevino M, Birdsong G, Carrigan A, Choyke P, Drew T, Eckstein M, et al.
JNCI Cancer Spectr
. 2022 Jun;
6(1).
PMID: 35699495
Medical image interpretation is central to detecting, diagnosing, and staging cancer and many other disorders. At a time when medical imaging is being transformed by digital technologies and artificial intelligence,...
4.
Wheeler D, Takebe N, Hinoue T, Hoadley K, Cardenas M, Hamilton A, et al.
Cancer Cell
. 2020 Nov;
39(1):38-53.e7.
PMID: 33217343
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic...
5.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M, et al.
Neuro Oncol
. 2020 Aug;
22(11):1706-1707.
PMID: 32823280
No abstract available.
6.
Eary J, Shankar L
Radiol Imaging Cancer
. 2020 Jun;
2(3):e204017.
PMID: 32550601
No abstract available.
7.
Boxerman J, Quarles C, Hu L, Erickson B, Gerstner E, Smits M, et al.
Neuro Oncol
. 2020 Jun;
22(9):1262-1275.
PMID: 32516388
Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization...
8.
Conley B, Staudt L, Takebe N, Wheeler D, Wang L, Cardenas M, et al.
J Natl Cancer Inst
. 2020 Apr;
113(1):27-37.
PMID: 32339229
Background: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying...
9.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M, et al.
Neuro Oncol
. 2020 Feb;
22(6):757-772.
PMID: 32048719
A recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and...
10.
Litiere S, Isaac G, de Vries E, Bogaerts J, Chen A, Dancey J, et al.
J Clin Oncol
. 2019 Mar;
37(13):1102-1110.
PMID: 30860949
Purpose: The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with...